Skip to content

Neuromuscular Blockade Reversal Agent Effect on Postoperative Cognitive Function and Behaviour in Children

Comparative Effect of Neuromuscular Blockade Reversal Agent on Extubation Conditions, Postoperative Cognitive Function and Behaviour of School-aged Children Undergoing Ear Note Throat (ENT) Surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02455921
Enrollment
200
Registered
2015-05-28
Start date
2015-06-30
Completion date
2018-04-30
Last updated
2018-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia; Functional

Brief summary

The aim of this prospective randomized study is to investigate comparatively the effect of neostigmine-atropine versus sugammadex on speed and quality of recovery and on postoperative cognitive function & behavior in children undergoing ENT surgery under general anaesthesia.

Detailed description

The aim of this prospective randomized study is to investigate comparatively the effect of neostigmine-atropine vs sugammadex on time of achieving extubation, quality of recovery, postoperative cognitive function and behaviour of children undergoing ENT surgery under general anaesthesia. In this study after parental approval has been obtained, children with age 6-12 yrs undergoing tonsillectomy and/or adenoidectomy under general anaesthesia will be included. General anaesthesia will be performed using Total Intravenous Anaesthesia (TIVA) technique with continuous infusion of propofol and remifentanil. Rocuronium will be used to achieve neuromuscular blockade (NMB). Neuromuscular reversal will be performed using either atropine-neostigmine or sugammadex. Patients will be divided into 2 groups according to the type of NMB reversal agent used. Intraoperative monitoring will include Bispectral Index Sedation (BIS), SpO2, capnography, noninvasive measurements of blood pressure, heart rate and train of four (TOF). Children will be assessed preoperatively (one day before surgery and at the morning of day of surgery), intraoperatively, immediate postoperatively and will be followed up for 15 postoperative days. Additionally, parents will be cooperated and questioned. The primary end-points of the study include the comparative investigation of the effect of neostigmine-atropine vs sugammadex on time of achieving extubation, quality of recovery, and postoperative cognitive function of children. Secondary endpoints will include side effects, signs of residual neuromuscular blockade, agitation and postoperative behavioural changes of children. For this purpose the following scales and questionnaires will be used: 1. Emotionality, Activity, Sociability & Impulsivity (EASI) Scale 2. The Modified Mini-Mental State (3MS) Test - Version G Greek 3. Yale Preoperative Anxiety Scale 4. Aldrete score 5. Emergence Delirium (PAED) scale 6. Wong-Baker scale 7. Visual Analogue Scale (VAS) (0-10) 8. Child Post- Hospital Behavior Questionnaire (PHBQ)\] 9. Post discharge repeated questionnaire All the questionnaires will be translated, culturally adapted and validated in Greek. Analysis of the data will include pair wise T test in order to find statistical differences between the two techniques and regression analysis models in order to revile significant correlations between dependent and independent variables. Statistical analysis will be performed with the use of SPSS21 for Windows.

Interventions

DRUGneostigmine - atropine

Efficacy, safety and effect on cognitive and behavioural function

DRUGSugammadex

Efficacy, safety and effect on cognitive and behavioural function

Sponsors

Attikon Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

\- Children undergoing ENT surgery under general anaesthesia.

Exclusion criteria

* Parents refusal * Cognitive impairment * Difficulty in communication due to language issues * Psychiatric disorder * Severe systematic disorder * Known allergy to any drug used

Design outcomes

Primary

MeasureTime frameDescription
time of achieving extubation10 mintime of achieving extubation

Secondary

MeasureTime frameDescription
signs of residual neuromuscular blockade1 hournumber of participants with signs of residual
Behavioural functionup to 15th postoperative daychanges using Battery test

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026